South Africa’s appetite for weight-loss and diabetes treatments is reshaping the continent’s pharmaceutical landscape. Driven by surging demand, the local market for GLP-1 drugs has nearly doubled over the past year to hit R2.8 billion.
At the centre of this boom is Durban-based Aspen Pharmacare, whose flagship distribution of Eli Lilly’s Mounjaro now commands over 53% of domestic market share, with regional sales projected to cross R2 billion by 2027.
However, with brand-name treatments largely paid for out-of-pocket, Aspen is also advancing plans for lower-cost generic alternatives - a move that promises to democratise access and fundamentally alter the economics of obesity and diabetes care across the country.
Alongside its distribution of Mounjaro, Aspen is also advancing plans to introduce its own generic semaglutide medicine in South Africa and select international markets to capture lower-cost demand as relevant patents expire.
Mounjaro claims market leadership
Aspen, which distributes Mounjaro (tirzepatide) locally across sub-Saharan Africa, confirmed the drug has officially emerged as South Africa's market leader.
Mounjaro currently commands more than 53% of the total domestic GLP-1 market share, rapidly overtaking rival therapies.
The treatment’s clinical efficacy for weight management and type 2 diabetes has fuelled unprecedented consumer demand.
To capitalise on this momentum, Aspen is actively expanding Mounjaro's regulatory footprint across the continent, filing for market access in key regional economies including Kenya and Nigeria.
Strategic generic push and supply dependencies
While Mounjaro currently drives Aspen's commercial revenues, the company is preparing a broader international rollout of affordable alternatives.
The group plans to introduce an independently developed generic semaglutide candidate across South Africa and select global markets, subject to health authority clearances.
Semaglutide is the active pharmaceutical ingredient made famous by Novo Nordisk’s blockbuster therapies, Ozempic and Wegovy. However, Aspen’s proposed product is not Ozempic, but rather a generic copy designed to expand access as patent protections expire.
Aspen has already achieved a major international regulatory milestone for this portfolio after its Canadian subsidiary successfully secured regulatory approval from Health Canada for its generic semaglutide injectable.
However, despite winning Canadian authorisation, the commercial launch timing remains strictly dependent on securing active pharmaceutical ingredient (API) supply from its India-based manufacturing partner, Dr. Reddy’s Laboratories Limited.
Meanwhile, in its home market of South Africa, pricing details and launch dates remain undisclosed as Aspen continues to await local approval from the South African Health Products Regulatory Authority (SAHPRA).
The affordability divide
The arrival of generic alternatives could offer much-needed relief to a sector constrained by cost.
In South Africa, high rates of type 2 diabetes and obesity have driven massive consumer interest, but with brand-name GLP-1s largely paid for out-of-pocket, treatment costs remain prohibitive for lower-income patients.
Industry analysts expect generic semaglutide entry, which global benchmarks suggest could drop costs by up to 50%, to significantly improve affordability and curb the rise of unregistered, compounded copycats operating in private markets.
As experts note, offering safe, SAHPRA-approved alternatives at lower price points removes the financial incentive for consumers to risk using illicit formulations.
alyssia.birjalal@nationalmg.co.za